-+ 0.00%
-+ 0.00%
-+ 0.00%

Enveric Biosciences Receives USPTO Notice Of Allowance For Patent Application Covering Compositions Of Matter And Methods Of Use For Novel Class Of Aminated Tryptamine Derivatives

Benzinga·06/10/2025 13:07:31
Listen to the news

Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments

Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering compositions of matter and methods of use for a novel class of aminated tryptamine derivatives.

The patented compounds were designed through Enveric's proprietary discovery platform and represent a first-in-class approach to non-hallucinogenic psychedelic-inspired therapeutics. The compounds demonstrated low hallucinogenic liability in preclinical testing, including minimal Head Twitch Response (HTR) and reduced 5-HT2A receptor activation – two established indicators of hallucinogenic activity in rodents.